Longeveron® Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Core Viewpoint - Longeveron Inc. has received approval from the WHO for the non-proprietary name "laromestrocel" for its cellular therapy Lomecel-B™, marking a significant milestone in its development and potential commercialization [1][2][6]. Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs, with its lead product being Lomecel-B™, an allogeneic medicinal signaling cell therapy derived from the bone marrow of young, healthy adult donors [4][6]. - The company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty [4]. Product Details - Lomecel-B™ is a proprietary, scalable cellular therapy being evaluated for Alzheimer's disease and HLHS, a rare pediatric disease [1][6]. - The therapy utilizes medicinal signaling cells (MSCs) that play a crucial role in the body's repair mechanisms, potentially offering anti-inflammatory and regenerative benefits across various diseases [3][4]. Regulatory Designations - Lomecel-B™ has received multiple FDA designations: Regenerative Medicine Advanced Therapy (RMAT) and Fast Track for mild Alzheimer's disease, and Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS [2][4].